American PharmaceuticalPartners(Schaumburg, Ill) recentlyreceived FDAapproval for its abbreviatednew drug applicationfor carboplatininjection (liquid form) in a 600-mgmultidose vial. The product is the genericequivalent of Bristol-Myers Squibb Co'sParaplatin. Carboplatin is indicated for theinitial treatment of advanced ovariancarcinoma in combination with otherestablished approved chemotherapeuticagents, as well as for the palliative treatmentof patients with ovarian carcinomarecurrent after prior chemotherapy.Carboplatin 600 mg is preservative-freeand AP-rated. The product vials include alatex-free vial stopper, bar code, and "tall-man" lettering label enhancements tohelp differentiate carboplatin from othercommonly used platinum-based chemotherapieswith the same name suffix. Theproduct also is available in 450-mg (liquidand lyophilized), 150-mg (lyophilized), and50-mg (lyophilized) vials. For more information,visit www.appdrugs.com.